What is Tribute Pharmaceuticals Canada Financial Strength?
Tribute Pharmaceuticals Canada has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Tribute Pharmaceuticals Canada did not have earnings to cover the interest expense.
Tribute Pharmaceuticals Canada's debt to revenue ratio for the quarter that ended in Sep. 2015 was 0.96.
As of today, Tribute Pharmaceuticals Canada's Altman Z-Score is 0.00.
Competitive Comparison of Tribute Pharmaceuticals Canada's Financial Strength
For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tribute Pharmaceuticals Canada's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Financial Strength distribution charts can be found below:
* The bar in red indicates where Tribute Pharmaceuticals Canada's Financial Strength falls into.
Tribute Pharmaceuticals Canada Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Tribute Pharmaceuticals Canada's Interest Expense for the
months ended in Sep. 2015 was $-0.60 Mil. Its Operating Income for the
months ended in Sep. 2015 was $-0.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $11.36 Mil.
Tribute Pharmaceuticals Canada's Interest Coverage for the quarter that ended in Sep. 2015 is
| Tribute Pharmaceuticals Canada did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Tribute Pharmaceuticals Canada's Debt to Revenue Ratio for the quarter that ended in Sep. 2015 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Tribute Pharmaceuticals Canada has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description
Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBUFF has been successfully added to your